Tuesday, November 29, 2011

NVSR - NavStar Technologies Inc.

NVSR - NavStar Technologies, Inc. dd



About NVSR
NavStar Technologies, Inc. engages in the production and commercialization of products and services for tracking/monitoring and reporting on the location and condition of high value cargo, equipment, and other valuable and personal assets. It primarily offers commercial/business global positioning system (GPS) tracking and monitoring products and services. The company's products include vehicle/portable asset tracker used to track and monitor vehicles, cargo, and other assets like trailers and heavy equipment; electronic on-board recorder, which is mounted to the dashboard of the vehicles and connects with the engine to provide users display of the vehicles activity; and personal asset tracker, a self-contained unit, including a the GPS system, digital cellular functionality, antennas, and battery that can be worn/carried by an individual or placed on small high-value assets for monitoring the unit’s location while in transit even over large distances. It also offers software services, such as driving directions, weather reports, and services related to nearest vehicle to a location. The company primarily focuses on the trucking, delivery, and services industry. NavStar Technologies, Inc. is based in Anaheim, California.



NVSR Security Details
Share Structure
Market Value1 $2,486,252 a/o Nov 23, 2011
Shares Outstanding 24,862,520 a/o Sep 30, 2011
Float 194,400 a/o Sep 30, 2011
Authorized Shares 100,000,000 a/o Nov. 14, 2011 (per last quarter report)
Par Value 0.001

Security Notes
* Capital Change=shs decreased by 1 for 24 split Pay date=07/30/2007.
* Capital Change=shs decreased by 1 for 10 split Pay date=08/19/2008.
* Capital Change=shs decreased by 1 for 150 split Pay date=12/16/2009.
* Capital Change=shs decreased by 1 for 100 split. Pay date=08/29/2011.

Shareholders of Record 1,518 a/o Sep 30, 2011
Financial Reporting/Disclosure
Reporting Status Alternative Reporting Standard
Audited Financials Not Available
Latest Report Nov 14, 2011 Quarterly Report
CIK 0001315049
Fiscal Year End 12/31
OTC Market Tier OTC Pink Current
SIC - Industry Classification 3699 - Electrical equipment and supplies, misc
Business Status Development Stage Company a/o
Incorporated In: NV, USA
Year of Inc. 2003
Company Notes
* Formerly=European Diversified Holding Company until 7-07
* Formerly=European Day Spa & Tanning Salon Holding Company, Inc. until 7-02
* Formerly=Scotties Fish & Chips, Inc. until 8-01

http://www.otcmarkets.com/stock/NVSR/company-info

Transfer Agent
Corporate Stock Transfer, Inc.
3200 Cherry Creek Drive South
Suite 430
Denver, CO, 80209
303-282-4800

Attorney Letter with Respect to Current Information
http://www.otcmarkets.com/financialReportViewer?symbol=NVSR&id=65743

Source: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com
(these are only sources and not always up to date)



NVSR Products & Services

http://www.navstarinc.com/_FileLibrary/FileImage/NSTRAK_EOBRPresentation.pdf

Vehicle/Portable Asset Tracker (VAT)
Vehicle/Portable Asset Tracker NavStar has been able to leverage improvements in GPS and wireless technology to create a new tracking device that is smaller and more compact than its Vehicle/Asset Tracker (VAT).

This product will enable the Company to track and monitor vehicles, cargo and other high value assets like trailers, heavy equipment, and just about anything that a customer deems as valuable.Tracking of vehicles for small to large trucking fleets is the main focus of the Vehicle/Portable Asset Tracker.

The NavStar EOBR
Mounted to the dashboard of the vehicles and connects with the engine. Information gathered from the engine, along with the GPS monitoring the unit provides, will give users an accurate display of the vehicles activity, and will be compliant with FMCSA regulations pertaining to the accurate recording of the drivers Hours of Service (HOS).

The unit will transmit required data to a secure server for the Trucking companies to monitor, and the software provided by NavStar will fulfill all HOS regulations. The indiviual unit will also be able to send, or print, driver log books required for FMCSA HOS inspections.

Since the unit will have GPS capabilities, it will also be able to assist the company in managing the costs assoicated with the operations of their vehicles and fleets. The company will be able to monitor the drivers activities and manage changes that might result in better gas mileage and other cost saving factors.

Other benefits include asset tracking, and vehicle recovery. The use of NavStar's EOBR units will greatly enhance the recovery of stolen vehicles and/or merchandise.

Personal Asset Tracker
The Personal & Asset Tracker is fully self-contained unit, including a the GPS system, digital cellular functionality, antennas and battery.

Smaller than a deck of cards and weighing only 5 ounces, the unit is portable and can be worn/carried by an individual or placed on small high-value assets for monitoring the unit’s location while in transit – even over large distances.

Once the units are powered on, they will automatically begin reporting their position - or remain “silent” depending upon the chosen configuration. Monitoring of the units can take place immediately via a subscription Internet service.

Software Services
Our GPS Tracking application covers all continental USA, Canada and Puerto Rico. The maps we use provide maximum quality and ease of use. Some of the features we offer are:
* Driving Directions
* Weather Reports
* Nearest vehicle to a location

GPS Tracking System Features
We offer a GPS Tracking system that has been developed completely based on the experience and feedback of our business team but most importantly on the experience of our customers. Our GPS Tracking solution is in an ever-changing process, based on two main streams:

* The changing needs of our customers
* The new opportunities offered by technology advances

Our GPS Tracking / Fleet Tracking System gives answers to these and many other questions:

* Where your drivers are
* Where and when they have gone
* How long have they been there
* How is the weather or the traffic on their zone
* Directions to get to the next stop
* Closest vehicle to a given location
* What driver is speeding
* When a vehicle enters or leaves a defined zone

Mobility
With our GPS Tracking system you will be able to monitor the location and status of your vehicles whenever, wherever. GPS Location, Track speed, direction, address and more using a portable device with browsing capabilities.


Technology
You will be using the best GPS GPRS devices in the market to get continuous reporting and great flexibility.

Keep this powerful tool and get...

* Locating Vehicles & Crews
* Theft Monitoring & Alerts
* Remote Door Lock Control
* Excessive Speed Monitoring
* Fuel, Engine, Door, Battery Temp. Monitoring
* Remote Ignition Control
* Unauthorized Vehicle Usage Alerts
* Roadside Assistance Request
* Verify accuracy of time sheets, mileage reports, call reports
* Ensure accurate customer billing for time & material work
* Reduces your vehicle insurance rates
* Increased Safety



NVSR Customers

Fix Group Fix Equipment S.A., Ecuador
This is for Fleet Management System (FMS) box and Mobile Display Unit (MDT) to distribute to Public Transportation System In Ecuador.

IntelliSOL Corporation
This is to be used in Automatic Vehicle Location (AVL), Stolen Vehicle Recovery (SVR) and Fleet Management System (FMS).

Diamente, Mexico
Mexico just passed regulation to have tracking system in all of new commercial vehicle sold in Mexico City in 2008. Diamente is one of few “approved vendors” in Mexico for this task and they are currently engaged in contract discussion with major vehicle manufacturers for Mexico Market. Diamente purchased test units and validate functionalities of system and they will launch this product in 3rd qtr of 2008.

Navmex, Mexico
Navmex has been distributing our products for past 18 months and this is a sign of distributorship growth in Mexico.

AVL, Canada
Following the successful evaluation of our units, and many in depth discussions of this date, Radio Service LCT intent to purchase from NavStar during next 12 months, minimum 1,000 units to be completed of a combination of following products, namely:
FMS-G (CDMA-GSM) – WOV (Without Voice) Unit
FMS-G (CDMA-GSM) – WV (With Voice) Unit
FMS-G (GSM) – Slim (Smaller, affordable) Unit in late 2nd Qtr or early 3rd Qtr.

The products are to be deployed in vehicle and asset tracking, security related applications employing Automatic Vehicle Location (AVL), Stolen Vehicle Recovery (SVR) and Fleet Management Systems throughout Mexico and other Latin American countries and North America.

Wise Track/Brazil Vivo
Wise has already taken delivery of the first 1,200 units. This customer has successfully launched solution in Brazil and selling quite well. Brazil is an important market as it opens the doors for many other countries in South America.

CANTV
CANTV is the parent company of Movilnet (CDMA Carrier) in Venezuela.

Secusat - Latin America
NavStar has developed and is manufacturing a line of Location Based Service (LBS) products, primarily focusing on Fleet Management Systems (FMS), Stolen Vehicle Recovery (SVR), security and risk mitigation service solutions. Secusat provides a hosted, end-to-end private labeled wireless location fleet management, stolen vehicle recovery, security and risk mitigation service solutions for wireless operators, insurance firms and security companies across Latin America.

GeoSoft – USA
GeoSoft has been selling Fleet Management systems for several years. They have selected NavStar products as their choice.



NVSR Recent News

NavStar Technologies Signs Agreement With Trinity Noble, LLC to Add Cell Phone Detection Feature to EOBR Hardware and Service Offering
11/22/2011 8:30AM - Market Wire

NavStar Technologies, Inc. Announces $2.4 Million in Funding From Southern California Investor Group
11/03/2011 9:00AM - Market Wire

NavStar Technologies, Inc. Restructures and Positions Company for Significant Growth in 2012
08/29/2011 9:30AM - Market Wire

NavStar Technologies, Inc. Announces Upgrade From Limited to Current Information at OTC Markets
06/17/2011 9:03AM - Market Wire

NavStar Technologies to Partner With Trinity-Noble to Provide Cell Phone Detection Usage With EOBR Hardware and Service
06/10/2011 9:00AM - Market Wire

Read more: http://www.nasdaq.com/aspxcontent/newsHeadlines.aspx?symbol=NVSR&selected=NVSR&SourceCode=PMZ#ixzz1eibZWuIO



NVSR Management Team

Chairman & CEO N. Douglas Pritt
has 30 years experience at senior level positions in the telecommunications industry. Mr. Pritt has served as President & CEO of OnFiber Communications, Senior VP of Business Development at Sprint PCS, and various senior level management positions at Lucent Technology.

Jason Shin serves as President and CTO.
Mr. Shin has served as Argo Chief Executive Officer and President since January 2003. Jason managed some of Interstate Electronics’ most important military GPS programs prior to leaving the firm to establish Axiom Navigation where he raised over $18 Million in equity financing. Jason Shin, assumed the role of President & CEO of Axiom Navigation and has worked for Rockwell Industries in their GPS divisions.

Patrick Bannister serves as CFO and possesses over twenty years of experience in the Technology and Financial Services spaces. Pat holds a CPA designation in California, as well as several securities industry licenses. In addition, he has experience with a Big 4 Public Accounting Firm, is experienced in the Finance, Accounting and Operations of businesses of varied sizes and industries.

Chief Scientist and Advisor Charles LaRue
has worked for many aerospace companies developing airborne radar systems, avionics operating and maintenance software, graphics software, aircraft simulation, and IFF systems. These companies include Lockheed, ITT Gilfillan, Teledyne, and Litton. In the mid-80’s he first conceived the idea of a car navigation system that gave turn-by-turn directions to the driver and has continued to advance the state-of-the art in voice navigation systems.




NVSR Contact Info
NavStar Technologies, Inc.
800 South Harbor Blvd.
Suite 220
Anaheim, CA 92805

Website: http://www.navstarinc.com
Phone: 714-502-6900
Email: info@navstarinc.com

As Always: Our Number 1 Priority is to educate. Penny stocks are very volatile, Always do your own Due Diligence

Sources: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com, NVSR website, www.businessweek.com
(these are only sources and not always up to date) 

9WV5UBKN4TH7 Follow Us on Facebook http://www.minataurgroup.com/ http://www.stockgoodies.com/

Tuesday, November 15, 2011

Davi Luxury Brand Group - MDAV

 Davi Luxury Brand Group - MDAV





Davi Luxury Brand Group - MDAV


ABOUT DAVI - MDAV
IN 1966, Robert Mondavi founded a winery with a mission to create a California wine that would stand up to the elite wines of the world. The result is a brand synonymous with quality and California wines the world over.
Forty years later, his grandson Carlo Cesare Mondavi has ventured out from his family’s sacred Napa Valley vineyards to create something alike in the skincare business—a luxury product that not only reflects the California lifestyle fostered by his family’s wine, but performs better than the already established skincare regimes available today.
He turned to what he knew best, as a third generation vintner, Carlo Mondavi has created a line of skincare with roots firmly planted in his family’s vineyards.
The result is Davi, a new line of luxury skincare encompassing the unique byproducts of the winemaking process coupled with the latest innovations in modern technology.
The company markets skincare products under the “DAVI Skin” and “DAVI” brand names. The products currently are provided as amenities at prestige hotels and as first class in-flight airline amenities.
The company’s goal is to also market its branded skincare products through upscale department stores, specialty retailers, prestige resorts, salons and spas, on cruise ships, and through airline duty-free shops.

The company’s skincare products contain minerals, vitamins and nutrients that are found in a by-product of the wine making process called the pomace.
Planting techniques at select vineyards produce deeper vines with a lower yield of grapes per vine. After processing, these grapes yield higher concentrations of minerals, vitamins, and nutrients than grapes from other vineyards. Additionally, the uniquely long maceration process to which these grapes are subjected, yield polyphenols in relatively high quantity.
Polyphenols are the free radical scavengers that, among other things, help to protect collagen and elastin fibers and prevent the destruction of hyaluronic acid in the skin.

Management believes that the use of this pomace will allow for the creation of skin crèmes that can help fight the natural aging process of the skin.
AT THE CORE of all our products is a proprietary microencapsulated anti-aging antioxidant complex called Meritage.
Created in close collaboration with laboratories in Lyon, France, Meritage is a unique blend of grape and fermented wine extracts, green tea, raspberry, black currant and bilberry extracts, rosemary and olive leaf extracts. Meritage is created through a unique double fermentation process and preserved in the formula until the moment it is applied to the skin.
Because it is microencapsulated, the select high-level antioxidants of Meritage are able to remain active on the skin hours longer than conventionally created products. Meritage's sustained time-release technology provides a slow infusion of antioxidant health benefits to the skin. A daily regimen of Davi skincare restores and rejuvenates, leaving your skin the picture of health—young, radiant and full of life.



PRODUCTS and SERVICES



Womens Collection


Le Grand Cru for Women
Nourish Protect Restore



The centerpiece of the women's treatment line, Le Grand Cru is an ultra luxurious cream designed to provide a long-lasting slow-released infusion of antioxidants and moisture to the skin, leaving skin smoother, softer and more supple.
Le Grand Cru focuses on a woman's skin needs by providing intense hydration, transforming dry, dull skin into a younger, more radiant complexion. Formulated with moisturizing shea butter, rosemary, green tea, grape extracts and vitamin E to fight free radicals, and our exclusive Meritage anti-aging complex, all blended to create the ultimate anti-aging cream for women.

Application:
To activate the meritage creme and release its key ingredients, warm a small amount between your fingertips.
As you pat onto clean, dry skin, you will instantly feel the soothing effects of the blend. Smooth over your face, neck, even under the fragile eye area. Apply day and night – for a lifetime.

VINE FRESH SPF 30 LOTION
An everyday light moisturizer with UVA/UVB protection of SPF 30. Vine Fresh SPF 30 Lotion provides the skin with nourishment and protection from the sun, leaving a healthy, radiant glow.
Formulated with shea butter to moisturize, bioactive ingredients from the healing herb centella asiatica to bring youthfulness and radiance to the skin, vitamin E and white tea to fight free radicals, spring sea water from Ile Grande on Cote de Granit Rose in Northern Britain to nourish the skin, and our exclusive Meritage anti-aging complex






MOSCATO PURIFYING CLEANSER

A luxuriously gentle creamy cleanser and conditioner. Moscato Purifying Cleanser leaves skin smooth and silky.
Formulated with glycerin for effective cleansing, coconut derived emollient and grapeseed oil for smooth, lustrous skin, and our exclusive Meritage anti-aging complex.

HARVEST MIST TONER

A super hydrating spray mist for toning, hydrating, and refreshing dull looking skin. Harvest Mist Toner improves overall balance as it soothes.
Formulated with witch hazel and extract from the mushroom polyporus officinalis to improve skin's tone and firmness, grapeseed oil for enhancing the skin's radiance and glow, and our exclusive Meritage anti-aging complex

LE GRAND CRU

The centerpiece of the women's treatment line, Le Grand Cru is an ultra luxurious cream designed to provide a long-lasting slow-released infusion of antioxidants and moisture to the skin, leaving skin smoother, softer and more supple.
Le Grand Cru focuses on a woman's skin needs by providing intense hydration, transforming dry, dull skin into a younger, more radiant complexion. Formulated with moisturizing shea butter, rosemary, green tea, grape extracts and vitamin E to fight free radicals, and our exclusive Meritage anti-aging complex, all blended to create the ultimate anti-aging cream for women.

brochure for women: http://www.daviskin.com/womens-brochure/





LE GRAND CRU for Men





The linchpin of the men's line, Le Grand Cru is an ultra-luxurious cream designed to provide an infusion of antioxidants and moisture to the skin.

Le Grand Cru addresses concerns particular to a man's skin, including irritation and dryness. Formulated with moisturizing shea butter, free-radical-fighting antioxidants such as rosemary, green tea, grape extracts and vitamin E, as well as ginseng, witch hazel and allantoin, a botanical extract of the comfrey plant, for toning and astringent benefits, and our exclusive Meritage anti-aging complex.

CRUSHED GRAPE SEED EXFOLIATING CLEANSER

An innovative cleansing formula to gently remove and exfoliate excess oil and dead skin cells in preparation for a clean shave.
Crushed Grape Seed Exfoliating Cleanser is formulated with moisturizing Bilberry, Soybean, Raspberry, and Olive Oil, exfoliating Grapefruit Powder and free radical fighting antioxidants Vitamin A, Vitamin E and Vitamin C, along with our exclusive Meritage anti-aging comple

RESERVE SHAVE CREAM

A moisturizing daily shaving cream perfect for any skin type.
Reserve Shave Cream is designed to provide the closest shave, leaving the skin smooth and sleek. Formulated with free radical fighting antioxidants such as grape leaf extract, green tea, vitamin E and vitamin C, along with our exclusive Meritage anti-aging complex.


DAVI5




VINE FRESH SPF 15 LOTION

A light, non-greasy everyday moisturizer with UVA/UVB protection of SPF 15.

Vine Fresh SPF 15 Lotion provides the skin with nourishment and protection from the sun, leaving a healthy, radiant glow. Formulated with shea butter to moisturize, bioactive ingredients from the healing herb centella asiatica to bring youthfulness and radiance to the skin, vitamin E and white tea to fight free radicals, spring sea water from Ile Grande on Cote de Granit Rose in Northern Britain to nourish the skin, and our exclusive Meritage anti-aging complex.

COASTAL VINE AFTERSHAVE

A refreshing after shave serum to calm, cool and close pores and to aid in the prevention of irritation.

Coastal Vine After Shave's soothing properties reduce redness and irritation caused by the shaving process. Formulated with free radical fighting antioxidants such as fermented wine extract, green tea, vitamin E and vitamin C along with ginseng and witch hazel for toning, and our exclusive Meritage anti-aging complex.

brochure for men: http://www.daviskin.com/mens-brochure/









MDAV Management Team

Parrish Medley
Chief Executive Officer, Secretary, Director and President


Officer since February 2010
48 Years Old
Parrish Medley currently is the President and Chief Financial Officer of Regal Group, Inc. Group, Insince February 2010. Mr. Medley also has been a member of the Board of Directors of Regal Group, Inc. since February 2010 and its President since August 2010. Regal c. is a public company engaged in the business of developing and integrating off-the-shelf and proprietary RFID solutions.

Mr. Medley co-founded Davi Skin, Inc. in 2003 and subsequently served as its President until December 2006. Between 2006 and 2010, Mr. Medley was involved in real estate and venture capital investments for his own account. Mr. Medley was a venture capitalist and a private money manager from 1997 to 2004. His previous experience includes roles as manager and financial consultant for numerous registered broker dealers, including Bear Stearns & Co. From 1999 to 2001 he was a partner at century financial partners a venture capital firm.

Mr. Medley also founded Palm Beach Tan one of the nation?s largest indoor chains and franchise operations as well as Mystic Tan one of the largest spray on tanning systems in the world doing combined revenues approaching 100 million dollars.

Effective December 30, 2010, Upon Mr. Beddome?s resignation, Parrish Medley became Chief Executive Officer, interim Chief Financial Officer, and Secretary of the Company. Prior to Mr. Rice?s appointment as the Company?s Chief Financial Officer, Parrish Medley, the Company?s President, Chief Executive Officer and Secretary, acted as the Company?s interim Chief Financial Officer.
http://people.forbes.com/profile/parrish-medley/92163

J. Bernard Rice
Director and Chief Financial Officer


Beverly Hills , CA
Officer since February 2011
Director , Omni Ventures, Inc.
56 Years Old

Effective April 27, 2011, Davi Luxury Brand Group, Inc. appointed J. Bernard Rice to serve on the Board of Directors of the Company. J. Bernard (Bernie) Rice ? Mr. Rice began his career with IBM in sales as a medical specialist in Atlanta in 1977.

In 1983, Mr. Rice entered IBM?s finance fraternity and was an active pioneer of IBM?s business approach to software as a strategic imperative. His work in business case structure and portfolio analysis led him to a role as IBM?s finance director for application software in 1985. Reporting directly to the General Manager, Mr. Rice was responsible for the financial management of over 6,000 IBM software developers, responsible for over $500 million in annual company revenues.

Mr. Rice joined IBM?s corporate financial team in 1987 and led the company?s restructuring effort. Mr. Rice was promoted to Executive Assistant to IBM Chief Financial officer in 1989. In this role he led several cross?industry executive groups who initiated IBM?s first Enterprise agreements with top customers.

Mr. Rice was named Director of Finance, Planning and Administration for IBM?s Southern Area in 1990. There he had responsibility for the staff functions comprising over $3 billion in IBM revenues. Mr. Rice was instrumental in positioning IBM?s southeast region as the leader in billable services. In 1993, Mr. Rice became Chief Financial Officer and General Partner for IBM Venture Capital Group. In this role Mr. Rice was highly involved with IBM?s ventures with Apple Computer, Blockbuster Entertainment Joint Ventures, and investments in the Media Industry and video on demand pilots with Bell Atlantic and Cox Cable.

Mr. Rice also was responsible for managing IBM?s first steps in the consumer software arena. Mr. Rice became VP of Business Development for IBM?s Consumer Division in 1998. Mr. Rice also served as CEO of Edmark, Inc., IBM?s subsidiary which developed innovative educational software for kids.

In late 2000, he orchestrated the successful spin?off of IBM's education content assets into Riverdeep, Inc., after which he became the Executive VP responsible for all sales and business development. Mr. Rice was a vital part of Riverdeep's explosive growth, helping it to become the fastest growing educational software company in the United States. Today Riverdeep has educational products in 45,000 schools in over 20 countries.
http://people.forbes.com/profile/j-bernard-rice/152618

Carlo Mondavi
Chairman of the Board


Beverly Hills , CA
30 Years Old
Carlo Cesare Mondavi, Chairman of the Board is a member of the Mondavi winegrowing family from Napa Valley, California. Mr. Mondavi worked at the Robert Mondavi Winery from 1987 until 2003.

Since 2008 he has worked at Continuum Estate with the sales team where he currently serves as the Western Regional Sales Manager. Continuum Estate is an artesian winery that was founded in 2005 by his grandfather Robert Mondavi and father Tim Mondavi. Mr. Mondavi studied International Business at the University of Aix en Provence, France and Language Studies at the University of Milan, Italy. He founded Davi Skin, Inc. in 2003 with the vision of improving skin health with the luxurious antioxidants found in wine and grapes. He resigned as an officer and director from Davi Skin, Inc. in July 2008.
http://people.forbes.com/profile/carlo-mondavi/25317

Carlo Mondavi is the grandson of American Icon Robert Mondavi (Founder of Robert Mondavi Winery, and co-founder of Continuum Winery Estate) where through his grandfather and family instilled in him was a legacy of family values and business ethics that he honors vigorously.
Mr. Mondavi began working at the Robert Mondavi Winery in 1987. He now sits on the family council of Continuum Estate and actively participates in the wine business and Continuums special events for sales and marketing.





RECENT PRESS RELEASES


Tue, Jul 05, 2011
DAVI LUXURY BRAND GROUP Appoints Shaun Wylie as Chief Operating Officer - Business Wire

Mon, May 09, 2011
Davi Luxury Brand Group Inc Announces Today It Has Engaged Hansam Moolsan Co., LTD for Its Duty Free Business in the Airline Industry. - Business Wire

Mon, May 02, 2011
DAVI LUXURY BRAND GROUP Announces a Multi-Year Agreement with KOREAN AIR to Be the Exclusive First Class and Business Class In-Flight Amenity Provider for All KOREAN AIR Flights Worldwide - Business Wire

Wed, Apr 27, 2011
DAVI LUXURY BRAND GROUP Announces J. Bernard Rice to Join Board of Directors -Business Wire

Mon, Mar 14, 2011
DAVI LUXURY BRAND GROUP, INC. Announces Reality TV Star Taylor Armstrong as Spokesperson for DAVI Skin Care - Business Wire

Wed, Feb 23, 2011
DAVI LUXURY BRAND GROUP is Pleased and Honored to Be the In-Room Amenity Provider for All Peninsula Hotels Worldwide - Business Wire

Tue, Feb 22, 2011
DAVI LUXURY BRAND GROUP Is Pleased and Honored to Be the in Room Amenity Provider for All Peninsula Hotels Worldwide - Business Wire

Fri, Feb 18, 2011
Company Profile for DAVI LUXURY BRAND GROUP, INC. - Business Wire

Wed, Feb 16, 2011
DAVI LUXURY BRAND GROUP Appoints J. Bernard Rice as Chief Financial Officer -Business Wire

Tue, Jan 25, 2011
Davi Luxury Brand Group, Inc. Announces Name Change and New Ticker Symbol - PR Newswire





CONTACT MDAV

MDAV Contact Info

Davi Luxury Brand Group
9426 Dayton Way
Beverly Hills, CA 90210
Office: 310.288.8393
Fax: 310.288.0125
info@daviskin.com
website: http://www.daviskin.com
facebook: http://www.facebook.com/mdav.davilux

Sources: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com, MDAV website, www.businessweek.com
(these are only sources and not always up to date)

9WV5UBKN4TH7   http://www.stockgoodies.comhttp://www.minataurgroup.com/   Follow Us on Facebook

Thursday, November 10, 2011

Force Fuels Out with Breaking News to Expand their Acreage in Kansas


$FOFU Force Fuels Enters Discussion With Pioneer Oil to Purchase 2000 Acres in Southeast Kansas



COSTA MESA, CA--(Marketwire -11/10/11)- Force Fuels, Inc. is a dual exchange listed Company on (OTC.BB: FOFU.PK - News) (OTCQB: FOFU.PK - News) (Pinksheets: FOFU.PK - News). With the completion of Reservoir Pressure Program Force Fuels has entered discussions to expand its holdings in Kansas by over 40%.

"Growth of this size is critical at this phase in our company. Although our stock prices have trended down our company has continued to grow. In the past few months we have completed our geological and drilling plans and prepared to start drilling new wells. Moving forward with our plans and adding this much land to our portfolio of Oil and Gas rich properties, we can continue to buy and sell properties while drilling new wells," said Tom Hemingway, President and CEO.

Force Fuels, Inc. has entered into discussions with Pioneer Oil Development in regard to a Joint Venture development project in Southeast Kansas next to their existing properties. The project includes a 2000 acre oil and gas field that has multiple production zones both for oil and gas. Final contract details are planned to be completed by end of the year and will fit well into our 2012 growth plans. The new well expansion program will commence with the new loans Force Fuels has applied for.

Once Force Fuels has completed the geological analysis and field studies by Carroll Energy, our local engineering partner, the Company can then move forward with the final new well drilling plan. Once the loans are approved and funded, Force Fuels will schedule the drilling contractor and other service work as needed for 15 new wells.

About Force Fuels, Inc.
Force Fuels, Inc.'s primary products of the company are regulated and standardized energy-based products, which do not require marketing or sales force, thus completely eliminating the related expenses. These energy-based products include oil, natural gas, solar, wind and hydrogen. In the oil and gas field the company plans to focus on the purchase of marginally producing shallow oil wells, which are relatively inexpensive to operate and can be optimized with existing technologies; the purchase of leases with potential for additional drilling in proven producing areas; and the acquisition of in-house know-how to further optimize production through stimulation, refurbishing and site optimization.

More information can be obtained at www.ForceFuels.com -- (949) 783-6723

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Contact:

PR Financial Marketing LLC
James Blackman
Tel: 713-256-0369
Email Contact

http://finance.yahoo.com/news/Force-Fuels-Enters-Discussion-iw-646377728.html?x=0&l=1

9WV5UBKN4TH7 Follow Us on Facebook http://www.minataurgroup.com/ http://www.stockgoodies.com/

CURAXIS Pharmaceuticals - CURX


CURAXIS Pharmaceuticals - CURX


About Us

Curaxis Pharmaceutical Corporation is a specialty pharmaceutical company dedicated to finding cures for major age-related diseases. Our initial focus is Alzheimer’s Disease (or AD).

Our lead product is a patented treatment that has shown the potential for treating and halting the progression of this devastating disease. Today, over 5,300,000 Americans suffer with Alzheimer’s Disease.
It is estimated that more than $100 billion is spent annually in the United States to treat and care for those with this ailment. Sadly, these numbers are growing every day as the situation for many patients and their families grows desperate, despite the millions of dollars spent annually to find the answer to effectively treating this disease.

Curaxis Pharmaceutical is moving to guide our patented treatment through the necessary clinical trials in order to make it available for patients as quickly as possible. Management believes this product represents a major new development in the battle against Alzheimer’s Disease. Currently, no medications or treatments halt or materially slows the progression of this disease. Our research results provide a very strong scientific explanation for the age-related onset of the disease, as well as its progressive nature.

Curaxis’ strategy is to initiate enrollment and dose the first patient in a Phase II clinical trial in women with mild to moderate Alzheimer’s disease in 2010. This major step for our Company will signify the next stage in the development of Curaxis Pharmaceutical and a major milestone towards commercialization of our premier product to treat Alzheimer’s Disease.

CURX On Alheimers Disease

Image


The 2011 Curaxis Pharmaceuticals Corp Annual Meeting of shareholders will be held on November 8th 2011. Please click here to download the proxy materials and to vote.

https://www.iproxydirect.com/index.php/CURX


Curaxis Pharmaceutical Corporation is a specialty pharmaceutical company dedicated to finding cures for major age-related diseases. Curaxis' initial focu s is Alzheimer's Disease (or AD). The lead product is a patented treatment, Memryte, that has shown the potential for treating and halting the progression of this devastating disease.
The Problem

Washington DC, May 19, 2010, A new report from the Alzheimer’s Association, “Changing the Trajectory of Alzheimer’s Disease: A National Imperative” shows that in the absence of disease-modifying treatments, the cumulative cost of care for people with Alzheimer’s from 2010 to 2050 will exceed $20 trillion in today’s dollars.

The new report is not all bad news, however, as it shows that Medicare and Medicaid can achieve dramatic savings - and lives could be significantly improved - with even incremental treatment improvements.

Harry John’s, President & CEO of the Alzheimer’s Association said, “ Today, there are NO treatments that can prevent, delay, slow or stop the progression of Alzheimer’s disease. While the ultimate goal is a treatment that can completely prevent or cure Alzheimer’s, we can see that even modest improvements can have a huge impact.”
Market Need - Curaxis Solution

Currently marketed Alzheimer's drugs target the symptoms of Alzheimer’s disease by enhancing some patients’ cognitive function and general behavior, but generally are not thought to slow progression of the disease.

Only about 50% of patients taking AChEIs (acetylcholinesterase inhibitors - current theory) experience a modest improvement in cognitive function. According to the Alzheimer’s Association, for those patients who show improvement, the benefit typically lasts for only six months to one year.

Based on preclinical and clinical results achieved to date, Curaxis believes that Memryte may substantially slow the progression of Alzheimer's disease and represent a significant clinical improvement over current drugs.


Corporate Office
Curaxis Pharmaceutical Corp.
1004 Chagford Way
Raleigh NC 27614
United States



Curaxis’ Theory

Curaxis’ scientific theory is novel yet consistent with current theories of Alzheimer's Disease (AD) and the major hypotheses regarding the cause(s) of Alzheimer’s disease.

Alzheimer's disease (AD) is a neurodegenerative disease that ultimately leads to death in afflicted individuals. Previous estimates suggest that there are 4.5 million people with AD in the U.S. alone, many of whom remain undiagnosed. A consensus report published in The Lancet in December of 2005 (1) stated new statistics about the current prevalence of AD and how it will increase in the future. This report estimates that the number of AD patients will double every 20 years to 42.3 million cases by the year 2020 and to 81.1 million cases by the year 2040. A more conservative estimate of AD prevalence published in Alzheimer's and Dementia in 2005 (2) predicted that the annual cost of AD to Medicare and Medicaid alone would exceed a trillion dollars per year by mid-century and AD will consume 4 of every 10 Medicare dollars.

AD research encompasses many therapeutic approaches that hold promise, but no researcher or company has demonstrated to date that they have an approach that will act in a "disease modifying" role, i.e., addressing the root cause of AD. Current Phase III AD trials are few in number and are generally designed only to demonstrate modest decreases in the rate of cognitive decline among AD patients. Several theories exist regarding appropriate biological targets to use in evaluating new therapies for AD. Many therapies under development depend on the theory that ß-amyloid accumulation (diagnostically known as amyloid plaques) is the cause of AD (3) and that removing it will benefit AD patients. Others examine the depletion of estrogen associated with menopause as a trigger for AD in aging women (4), while another theory suggests that sustained or higher testosterone levels may provide benefit to men with AD (5).



Image


Neurofibrillary tangles associated with the phosphorylation of the protein "tau", long time diagnostic hallmarks of AD, are also being investigated (6). Other scientists, including those at Curaxis, believe that dysregulation of the cell cycle in neurons may promote the neuronal cell death that leads to AD and that other AD-associated events result from that dysregulation (7, 8, 9). However, no consensus exists about the cause of AD or how to slow or stop its progression.

AD is a multifaceted disease that has many biochemical and physiological aspects that provide credence to each of the AD-associated theories mentioned above. Since AD is, first and foremost, a disease of aging and is likely multifactorial, it is reasonable to hypothesize that a biochemical change associated with aging might be the trigger for AD. It would also follow that if one identified the major trigger of AD, then it might be able to explain other aspects of AD. Curaxis’ scientific evidence to date supports the hypothesis that luteinizing hormone (LH) may be associated with several of the pathological processes that result in AD, and Curaxis’ scientific theory is congruent with many mainstream theories regarding how AD arises and how to effectively treat this disease.

This Video is Patrick Smith Of Curaxis Pharmaceutical Corporation - Alzheimer Disease
Lists him as CEO but he is no longer the CEO, but it explains Alzheimer's and the company Brilliantly!


Image



Milestones

Curaxis is committed to its mission of delivering a treatment for halting the progression of Alzheimer's Disease. The Company has made significant strides toward that goal. Some of the more recent accomplishments include:

June 2011 - The Company announced changes to its Board of Directors (the “Board”) and its executive management team to better position the Company for its next phase of growth and development.The new Board has a wealth of experience and comprehensive knowledge of life sciences, operations and strategic management in the area of pharmaceuticals. In addition, the newly appointed Board members have significant experience in the necessary industry arenas to execute the Company’s business plan on an accelerated basis.

July 2010 - The Company announced completion of its reverse merger (the "Merger") with Auto Search Cars, Inc. ("Auto Search"). As a result of the Merger, the company will concentrate exclusively on clinical development of Curaxis' drug pipeline.

October 2009 – Curaxis adds to the management team and board in order to guide the Company through all required development processes. Resources include internal and external experts in basic scientific research, drug development, manufacturing, clinical research and regulatory affairs.

2007 – Curaxis discovers genetic-specific differences in male and female AD brains relevant to treatment methodology.

2007 – Curaxis demonstrates that high doses of Memryte stop or slow tumor growth in numerous cancer cell lines.

2006–2007 – Curaxis demonstrates that Memrye stops tau phosphorylation and oxidative stress.

2006 – Curaxis discovers autocrine-paracrine signaling in neurons and many cancers. Management files applicable patents.

2005 – Working with Durect Corporation, Curaxis initiates first use of its proprietary implant with a unique delivery profile for use in treating Alzheimer’s disease.

2004 – Curaxis files for patents using Memryte and acetcholine inhibitors and NMDA receptor agononists.

2004 – Curaxis initiates an open label extension study for women who complete the one-year, double blind, placebo controlled Phase II trial.

2004 –Our Research Labs in Research Triangle Park commence studies in order to focus on further exploring Curaxis’ basic scientific hypothesis in a number of specific therapeutic targets.

2004 – Curaxis demonstrates that Memryte stops cell cycling-division and apoptosis.

2003 – Curaxis successfully initiates a one-year, double blind, placebo controlled Phase II clinical trial in men, designed to further demonstrate the efficacy and safety of a patented product in the treatment of Alzheimer's Disease.

2003 – Curaxis successfully initiates our double blind, placebo controlled, one year Phase II clinical trial in women to demonstrate the efficacy and safety of a patented product in the treatment of Alzheimer's Disease
The Company continues to build relationships and collaborate on additional research with a network of leading Alzheimer's researchers across the United States and in Australia. These efforts continue to generate important new data that supports our hypothesis and offers a strong scientific case for use of Curaxis’ patented treatment.
Curaxis’ research findings have been published in a number of respected, peer-reviewed journals. Most recently, we reported in the The Journal of Biological Chemistry, a link between the marked increases i n serum LH following menopause/andropause and Aß secretion and deposition in the aging brain.
Working with DURECT Corporation, a leading drug development company, Curaxis has completed initial development of a unique dose and delivery formulation for a patented Alzheimer's treatment.

In collaboration with recognized epidemiologists, Company researchers supported an epidemiological study that offers compelling data and findings, that further support the hypothesis and provides additional evidence of the potential efficacy of Curaxis’ proposed Alzheimer's treatment.
**All research and development of the Company prior to 2009 was carried out under the name Voyager Pharmaceutical Corp. Historical references and literature concerning Voyager Pharmaceutical, its research, developments and operations represent the legacy development of Curaxis Pharmaceutical.


Image


Pipeline

Our therapeutic platform is based on the hypothesis that many diseases of aging may be caused by age-related dysregulation of the hypothalamic-pituitary-gonadal (HPG) axis.
This platform is built on the premise that hormones associated with this axis are beneficial early in life, when they promote growth and development, but are harmful later in life when the mechanism for feedback is compromised, thereby leading to disease processes, including pathologies associated with Alzheimer’s disease and various cancers.
We believe our discovery of a duplicate HPG axis at the cellular level in brain tissue from Alzheimer’s patients and in multiple tumors will enable us to develop significant new treatments for Alzheimer’s disease as well as many cancers.


Our Alzheimer’s Disease Program

Leuprolide acetate, a peptide hormone, has been widely used over the past twenty years for the treatment of a number of hormone-related disorders, most notably prostate cancer and endometriosis and precocious puberty, and has a well-established safety profile. Voyager has conducted extensive preclinical and clinical studies exploring the use of leuprolide acetate for the treatment of Alzheimer’s disease in mild-to-moderate patients.
The results to date are very encouraging and point especially to a potentially significant new treatment for women with Alzheimer’s disease.
Women represent approximately two-thirds of Alzheimer’s patients.
Men present greater challenges in the use of leuprolide to treat Alzheimer’s disease because leuprolide suppresses their production of testosterone, which could necessitate patient self-administration of supplemental testosterone and which can lead to wide swings in testosterone blood serum levels.
Therefore, in the near-term, we plan to concentrate our development efforts on the use of leuprolide acetate to treat women, although we will continue our efforts to better understand mechanisms that might lead to optimum outcomes in men.



Our Oncology Program

We have conducted an extensive preclinical research program in the use of leuprolide acetate to treat a number of cancers, including hor mone refractory prostate cancer, brain cancers, kidney cancer, pancreatic cancer and non-small-cell lung cancer.

Our work in oncology is based on new insights into the growth of cancer cells that have been discovered by our scientists. In particular, our scientific findings relating to autocrine-paracrine signaling and the replication of the hypothalamic-pituitary-gonadal axis (the HPG axis) inside of cancer cells point to a previously unknown mechanism that drives the growth of cancer cells and an entirely new method of attacking those cancer cells; i.e., using high doses of leuprolide acetate to eliminate the gonadotropins that may be driving the growth of those cells.

Our preclinical testing of this new treatment approach has produced extremely encouraging results. In both in vitro and in vivo experiments, we have demonstrated a potentially important new therapy for the treatment of a number of cancers.

We plan to use the same compound for our various cancer Phase II clinical trials as we are using for clinical trials of VP4896. Since we have completed Phase I safety trials of VP4896, we believe that we will be able to commence our clinical programs for various cancers with Phase II clinical trials instead of Phase I safety trials. However, the FDA will have to agree to the commencement of these clinical programs with Phase II clinical trials when we submit our Investigational New Drug Applications, or INDs, to the FDA.

Disease Indication Development Status
Hormone refractory prostate cancer Ready for initiation of proof of concept clinical trials
Adult brain cancers (Glioblastoma, stage III, IV) Ready for initiation of proof of concept clinical trials
Renal cell carcinoma Ready for initiation of proof of concept clinical trials
Pancreatic cancer Ready for initiation of proof of concept clinical trials
Non-small cell lung cancer Preclinical testing to continue


Image


History

Curaxis’ history dates to an insight from the mid-1990’s concerning how changes in various hormone levels impact our health as we age. Most everyone knows that, as we age, our hormone levels change. In particular, it is well known that as we age, levels of estrogen decline precipitously in women, leading to menopause, and levels of testosterone gradually decline in men, leading to andropause. However, while a great deal of research has previously been devoted to the effects of declining estrogen and testosterone on our health, including our mental abilities, Curaxis has taken this research in a broader direction.
Specifically, Curaxis was founded in 2001 (as Voyager Pharmaceutical Corp.) to take a step back from a singular focus on estrogen and testosterone to examine the entire HPG axis, which regulates production of estrogen and testosterone throughout our lives. Curaxis’ initial hypothesis was that changes in the levels of hormones in this axis other than estrogen and testosterone play a key role in various diseases of aging. During 2001 and the years that immediately followed, Curaxis devoted substantial research to testing this hypothesis. Also during 2001, Curaxis was awarded a broad patent covering its unique approach to the treatment of Alzheimer’s.
As a result of Curaxis’ research, it became increasingly clear that one hormone of the HPG axis, called luteinizing hormone or LH, may play a central role in the pathologies that lead to Alzheimer’s as well as other diseases of aging, including many cancers. Levels of LH increase dramatically as women enter menopause and increase substantially in men as they age and testosterone production declines. In numerous preclinical studies, Curaxis’ research showed that these increased levels of LH were likely a key contributor to developing Alzheimer’s.



Image


CURX Partners

Curaxis has engaged a very impressive infrastructure of scientific/technical, medical and legal advisers as strategic partners. This allows the Company to leverage talented individuals who provide key knowledge, expertise and support. A selection of these partnerships is represented by:

• Our collaboration in discovery research with leading Alzheimer's research teams led by George Perry, PhD, Mark A. Smith, PhD http://www.cwru.edu/med/pathology
• Leading patent and FDA legal support from Covington & Burling http://www.cov.com
• Clinical and FDA regulatory support from Bert Spilker & Associates (http://www.bertspilker.com);
• Drug development and delivery support from DURECT Corporation (http://www.durect.com);
• Website and marketing communications support by Sage Communications, LLC. (http://www.cwru.edu/med/pathology)


Case Western Reserve University - Department of Pathology

World-class research is conducted in the Department of Pathology with major emphasis on the following areas and more: cancer biology, infection and immunity, neurobiology/neuropathology, tissue injury and healing, and biomaterials biocompatibility. These emphasis areas are reflected in the three tracks of the Pathology Graduate Program: the Cancer Biology Training Program (CBTP), the Immunology Training Program (ITP) and the Molecular and Cellular Basis of Disease Training Program (MCBDTP). The Pathology Graduate Program provides extensive opportunities for PhD or MD-PhD training in these areas. A separate program leads to the MS degree.

Covington & Burling LLP

Covington & Burling LLP represents clients in cutting-edge technology, litigation, white collar defense, transactional, governmental affairs, international, life sciences and other matters. In responding to the needs and challenges of our clients, our lawyers draw upon the firm’s expertise and experience in a broad array of industries to provide solutions to difficult, complex, and novel problems and issues, whether in litigation, transactions, or regulatory proceedings.

Bert Spilker & Associates

The mission of Bert Spilker & Associates (BS&A) is to provide clients with the highest quality, most cost-effective, and timely pharmaceutical consulting services available. To achieve this goal, Bert has assembled a group of over 150 independent associates who are available to assist him in most aspects of drug discovery, drug development and strategy setting. BS&A strives to build long-term relationships with clients based on knowledge of his clients culture, research, products and services.

Sage Communications Advertising and Public Relations

Sage Communications is a full-service, integrated marketing firm that provides advertising, public relations, and strategic marketing services to clients from across the street to across the globe, from emerging start-ups, to major Fortune 500 companies. Throughout our history, our mission has remained the same: Align marketing strategy to directly impact our clients' bottom line. We are located in Tysons Corner, VA


Image


CURX Recent News


RED HOTT

The 2011 Curaxis Pharmaceuticals Corp Annual Meeting of shareholders will be held on November 8th 2011.

Quote: Curaxis Pharmaceutical Corporation is a specialty pharmaceutical company dedicated to finding cures for major age-related diseases. Curaxis' initial focu s is Alzheimer's Disease (or AD). The lead product is a patented treatment, Memryte, that has shown the potential for treating and halting the progression of this devastating disease.
The Problem
Washington DC, May 19, 2010, A new report from the Alzheimer’s Association, “Changing the Trajectory of Alzheimer’s Disease: A National Imperative” shows that in the absence of disease-modifying treatments, the cumulative cost of care for people with Alzheimer’s from 2010 to 2050 will exceed $20 trillion in today’s dollars.
The new report is not all bad news, however, as it shows that Medicare and Medicaid can achieve dramatic savings - and lives could be significantly improved - with even incremental treatment improvements.
Harry John’s, President & CEO of the Alzheimer’s Association said, “ Today, there are NO treatments that can prevent, delay, slow or stop the progression of Alzheimer’s disease. While the ultimate goal is a treatment that can completely prevent or cure Alzheimer’s, we can see that even modest improvements can have a huge impact.”


Market Need - Curaxis Solution

Currently marketed Alzheimer's drugs target the symptoms of Alzheimer’s disease by enhancing some patients’ cognitive function and general behavior, but generally are not thought to slow progression of the disease.
Only about 50% of patients taking AChEIs (acetylcholinesterase inhibitors - current theory) experience a modest improvement in cognitive function. According to the Alzheimer’s Association, for those patients who show improvement, the benefit typically lasts for only six months to one year.
Based on preclinical and clinical results achieved to date, Curaxis believes that Memryte may substantially slow the progression of Alzheimer's disease and represent a significant clinical improvement over current drugs.

Aug 17, 2011 Curaxis Pharmaceutical Corporation Management Working Through Transition Phase and Evaluating Alternatives
Jun 27, 2011 Curaxis Pharmaceutical Corporation Announces Key Changes to Its Board of Directors and Management Team in Progression Toward Clinical Trials
May 10, 2011 Curaxis Pharmaceutical Corporation Chief Executive Officer Comments on Recent NIH Research
May 5, 2011 Curaxis' Memryte Named One of the Top 100 Drugs in Development Today by R&D Directions
Mar 24, 2011 Curaxis Pharmaceutical Corp. CEO Patrick S. Smith Comments on Recent Prana Research
Mar 10, 2011 Curaxis Pharmaceutical Corp. CEO Patrick S. Smith Comments on Recent New York Times Article "Drug Firms Face Billions in Losses in '11 as Patents End"
Feb 14, 2011 Curaxis Pharmaceutical Corp. to Meet With Ticino Business Development Office in Lugano, Switzerland
Feb 9, 2011 Curaxis Pharmaceutical Corp. Announces New Listing on the Frankfurt Stock Exchange
Feb 7, 2011 Curaxis Pharmaceutical Corp. CEO Patrick S. Smith Comments on Recent Alzheimer's Association Report
Feb 3, 2011 Curaxis Pharmaceutical Management on Roadshow in Europe to Access Capital & Pursue Strategic Partners


Image


CURX Core Management Team

Timothy R. Wright - Chairman and Interim Chief Executive Officer

A seasoned executive with over 25 years of life sciences experience, Timothy Wright has comprehensive operating and strategic management experience, which encompasses pharmaceuticals, medical device, diagnostics and pharmaceutical services. Prior to joining Curaxis as Chairman of the Board and interim Chief Executive Officer, Mr. Wright was a Senior Vice President and President of the pharmaceuticals division at Covidien (Mallinckrodt). He previously served as President of Global Operations at Elan BioPharmaceuticals and spent 17 years at DuPont Merck Pharmaceuticals, where he was classically trained in the pharmaceutical industry. He brings significant global operating and product launch experience and has served on the boards of four public and four private global life sciences companies.


Judith S. T. Geaslen - VP Finance

Judith S. T. Geaslen has been the Company’s Vice President of Finance and Chief Accounting Officer since August 2009 after serving as Corporate Controller and Accountant since July 2004. From March 1999 to April, 2000, Ms. Geaslen served as Vice President and Corporate Controller at Wilmington Trust Corporation, a financial holding company engaged in providing a range of banking and other financial services through its banking and other subsidiaries, and from 1994 to 1999, served as Vice President and Manager of the Asset Review Division. From September 1984 to September 1994, Ms. Geaslen was employed by Ernst & Young, a registered public accounting firm, mostly recently serving as Audit Senior Manager. Ms. Geaslen is a graduate of Saint Mary’s College, Notre Dame, Indiana.


Image


CURX Contact Info


Curaxis Pharmaceutical Corp
1004 Chagford Way
Raleigh, NC 27614
Website: http://www.curaxispharma.com
Phone: 888-919-2873
Email: jgeaslen@curaxispharma.com
twitter: http://twitter.com/#!/curaxispharma
facebook: http://www.facebook.com/pages/Curaxis-P ... 4304105704

9WV5UBKN4TH7 Follow Us on Facebook http://www.minataurgroup.com/ http://www.stockgoodies.com/

Wednesday, November 2, 2011

TBSS International - ANSH


TBSS International - ANSH

Image


ABOUT TBSS International - ANSH

TBSS International is a visionary development firm with a management team representing over 50 years of collective experience in winning competitive contracts on the strength of incorporating proprietary technologies from a network of venture partners. TBSS's has won construction and service contracts in the following industries:


Construction
Oil Drilling
Gold Mining
Water Well Drilling
Sonic and Horizontal Drilling

TBSS International has worked with a number of Fortune 500 companies requiring an emphasis on environmentally sound practices, in addition to smaller companies operating domestically and internationally. TBSS fulfilled a contract from Con Edison to reduce energy consumption by 30% throughout the Tristate area of New York, Connecticut and New Jersey.


Image


TBSS International’s network of industry professionals designed and implemented a more energy efficient florescent lighting system which surpassed expectations by reducing overall power consumption by 60%. Another client, Coca Cola and Company, used TBSS International to increase production at a bottling facility in Maspeth, New York (Queens). TBSS International coordinated and executed on a plant relocation plan as well as a complete redesign of the facility bottling system.
Smaller construction projects include converting a building shell into a seventeen unit apartment building for Finkelstein & Morgan Real Estate.
TBSS's mission is to educate and provide our clients with the most innovative technologies that reduces and minimizes our global carbon footprint while building shareholder value.


ANSH PRODUCTS and SERVICES


CONSTRUCTION


Image

The pricipals of TBSS International collectively have over 50 years of construction experience which spans a wide array of project types.
Our flexibility to meet community demands has afforded us the opportunity to work on anything from private residential renovations to 50 story office complexes.

Image

We pride ourselves on the ability to take a project from conception to a quality finished product while staying under time and budget constraints.
Regardless where a project is located, TBSS can mobilize quickly to bring the resources necessary for the timely completion of the project. Our reputation for quality execution has helped TBSS to develop a list of repeat clients that provide us with referrals .

Image


Sonic and Horizontal Drilling



Sonic Drilling:

TBSS International's network has been in the Sonic drilling business for over 5 years and its use continues to grow as the technology advance has been the solution to many challenges in the field. A sonic drill head sends high frequency resonant vibrations down the drill string to the drill bit. There has been many technological advances in Sonic Drilling over the last five years and TBSS International will remain on the cutting edge as this promising technology evolves.


Image

Image



Horizontal Drilling:


TBSS’s partners have been utilizing Horizontal (or slant) Drilling which enables access to oil reservoirs that are under towns, lakes or under a difficult to drill geological formation. Horizontal drilling also offers a very cost efficient method to have more wellheads clustered on one drilling platform with wells fanning out.


Image


Water Well Drilling


Image


Water Well Drilling:


TBSS International's partner network has been drilling fresh water wells over the past ten years, yet recent advancements in technology now include sonic drills. This technology has virtually replaced the use of drilling trucks, but TBSS has found that it is still beneficial to operate these trucks in emerging markets with minimal infrastructure.


Image


Oil Drilling

Image


The oil industry has changed dramatically over the years, but one thing remains the same--this is still a business of extracting the most oil out of every concession.


Image


TBSS International's network pushes the edge of that change with a patented water separation technology that separates oil from the water in the field, thereby eliminating a large part of the refining process. Besides being more cost and time effective, this technology increases the potential for additional production.


Image


Significantly, the separation process is so precise that it produces water pure enough to drink. This is beneficial in two ways. For offshore drilling, it eliminates the need to have fresh water delivered to the offshore platform to continue the down hole process. The same holds true when drilling on land with the additional environmentally-friendly benefit of recycling pure water back into the earth.



Gold Mining

Image

Our commitment to the environment and industry standards led us to seek out new and innovative means of extracting gold. While TBSS International’s network has extensive experience in open pit mining, we prefer a more scientific approach for environmental reasons. We use ground penetrating radar (GPR) to take a snap shot of the mineral reserves subsurface which allows our sonic drilling engineers to approximate the richest mineral deposits. GPR maximizes the client’s exploration budget while minimizing the destructive effects on the environment.

Image


RECENT PRESS RELEASES


Thursday, October 27, 2011
TBSS International, Inc. Launches Corporate Website
Newly Public Company Preparing for Required Press Release Distribution

TAMPA, Fla., Oct. 27, 2011 /PRNewswire/ -- TBSS International, Inc. (OTCBB:ANSH.ob - News) ("TBSS"), an international service company with existing service contracts assisting companies involved in gold mining and oil drilling, announced today the launching of the company's website at http://www.tbssinternational.com.

The company's recent entry into the public markets requires that the company prepare for the broad distribution of material information to its shareholders and the corporate website is an integral part of the dissemination of investor information.

The company previously announced that it is currently executing on contracts with initial revenues to be recognized in the current quarter. TBSS will be releasing financial details of each of these contracts in the near future through PR Newswire and its new website.

http://finance.yahoo.com/news/TBSS-Inte ... l?x=0&.v=1

Friday, October 21, 2011

AVENUE SOUTH LTD. FinancialsEDGAR Online Financials (Fri, Oct 21)

Friday, October 14, 2011

AVENUE SOUTH LTD. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Unregistered Sale of EquityEDGAR Online (Fri, Oct 14)

Thursday, October 13, 2011
TBSS International, Inc., an International Service Company, Begins Trading Under Symbol "ANSH"
Company's Licensed Technology Winning Service Contracts in Gold Mining and Oil Drilling

TAMPA, Fla., Oct. 13, 2011 /PRNewswire/ -- TBSS International, Inc. (OTCBB: ANSH) ("TBSS"), an international service company with existing service contracts to assist companies that have begun gold mining and oil drilling, as well as work on water well drilling, trenching and general construction, has begun trading under the symbol "ANSH" on the OTCBB. TBSS currently has exclusive regional rights to various technologies which have resulted in these contracts that are currently being fulfilled with initial revenues to be recognized in the fourth quarter of 2011.

Mr. Todd Spinelli, CEO of TBSS International, said, "TBSS has secured a number of contracts to facilitate existing companies engaged in gold mining, horizontal oil drilling and water separation in oil fields. The TBSS revenue is not dependent on finding or processing gold or oil and will be paid irrespective of the returns from such enterprises. Initial revenues will be booked in the fourth quarter with the preponderance of the revenues to be booked in the first quarter, 2012."

Spinelli continued, "Based on what we are seeing in the marketplace, we anticipate announcing a number of individual contracts now that we are no longer a private company. We will be informing our shareholders on our progress on an ongoing basis with more financial details in the near future."

http://finance.yahoo.com/news/TBSS-Inte ... l?x=0&.v=1


Thursday, October 6, 2011

AVENUE SOUTH LTD. Files SEC form 8-K/A, Change in Directors or Principal OfficersEDGAR Online (Thu, Oct 6)

Saturday, September 10, 2011

AVENUE SOUTH LTD. FinancialsEDGAR Online Financials (Sat, Sep 10)

Friday, August 19, 2011

AVENUE SOUTH LTD. Files SEC form 8-K, Change in Directors or Principal Officers, Other EventsEDGAR Online (Fri, Aug 19)
AVENUE SOUTH LTD. Files SEC form 8-K, Change in Directors or Principal Officers, Other EventsEDGAR Online (Fri, Aug 19)



ANSH MANAGEMENT TEAM



Todd A. Spinelli
President, CEO, CFO


Mr. Todd A. Spinelli has been Chief Executive Officer, President and Chief Financial Officer of Avenue South Ltd. since September 29, 2011. Mr. Spinelli has been the President/Owner of Global Electric Construction Corp. since 2002. Mr. Spinelli serves as Chief Financial Officer of Bel Ea Co. Mr. Spinelli served as Senior Executive Vice President at United Treatment Centers, Inc. He served with clients such as Coca-Cola, H.O. Penn Caterpillar, McDonald-Douglas and Zeus Military facility. He has been a Director of United Treatment Centers, Inc. since April 14, 2009. Mr. Spinelli has been a Director of Avenue South Ltd. since September 29, 2011.


Kim Spinelli
Secretary


Kim Spinelli has been Secretary and Director of Avenue South Ltd. since September 29, 2011. Kim Spinelli has been a private investor for the last 10 years


Image


CONTACT TBSS International



TBSS International, Inc.

9113 Ridge Rd. Suite 50
New Port Richey, FL 34654
website: http:// http://www.tbssinternational.com/
http://Email: info@tbssinternational.com

Phone:
(855)OIL-GOLD
(855)645-4653

Investor Relations Contact http://IR@tbssinternational.com
(855) 645-4653



We Will Continue Keep Our Members Informed On Any ANSH Updates In the Future!


Never Invest More Than You Are Willing To Lose


Sources: otcmarket.com, http://www.bloomberg.com, http://www.finance.yahoo.com, ANSH website, http://www.businessweek.com
(these are only sources and are not always up to date)

9WV5UBKN4TH7 Follow Us on Facebook http://www.minataurgroup.com/ http://www.stockgoodies.com/


9WV5UBKN4TH7 Follow Us on Facebook http://www.minataurgroup.com/ http://www.stockgoodies.com/